Palivizumab: Is it cost effective to extend the vaccination period for patients at risk of severe respiratory syncytial virus infection?

2021 ◽  
Author(s):  
Gemma Wilson ◽  
Louise Selby ◽  
Pravin Desai
Keyword(s):  
At Risk ◽  
Respiratory Syncytial Virus ◽  
Virus Infection ◽  
Respiratory Syncytial Virus Infection ◽  
Cost Effective ◽  
Severe Respiratory Syncytial Virus ◽  
Patients At Risk ◽  
Syncytial Virus ◽  
Vaccination Period

Association of TNF-α with severe respiratory syncytial virus infection and bronchial asthma

2009 ◽  
Vol 20 (2) ◽  
pp. 157-163 ◽  
Author(s):  
Beena Puthothu ◽  
Sibylle Bierbaum ◽  
Matthias V. Kopp ◽  
Johannes Forster ◽  
Jessica Heinze ◽  
...  
Keyword(s):  
Respiratory Syncytial Virus ◽  
Virus Infection ◽  
Bronchial Asthma ◽  
Respiratory Syncytial Virus Infection ◽  
Severe Respiratory Syncytial Virus ◽  
Tnf Α ◽  
Syncytial Virus
Sign in / Sign up

Export Citation Format

Share Document